Barchart.com
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Menu
alerts false
Stocks | Futures | Watchlist | News | More
 
Advanced search
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Aptinyx Inc (APTX)

Aptinyx Inc (APTX)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
0.0960 +0.0029 (+3.11%) 12/29/23 [OTC US]
N/A x N/A N/A x N/A
Post-market 0.0960 unch (unch) -
News & Headlines for Fri, Dec 29th, 2023
Help
Go To:
Aptinyx Reports on Fourth Quarter and Full Year 2022 Results and Highlights and Review of Strategic Alternatives Business Wire - Thu Mar 30, 2023

Aptinyx Inc. (Nasdaq: APTX) today reported recent business updates and financial results for the fourth quarter and full year 2022.

APTX : 0.0960 (+3.11%)
Wall Street - New York Stock Exchange NYSE
Stocks Mixed Before The Open As Fed Fears Persist, Target Earnings On Tap Barchart - Tue Feb 28, 2023

March S&P 500 futures (ESH23) are trending up +0.07% this morning after three major U.S. benchmark indices ended the regular session higher as investors digested an early round of U.S. economic data and...

ESH23 : 3,957.05s (-0.09%)
TSLA : 239.43 (-10.42%)
SGEN : 228.74 (-0.07%)
UNP : 213.26 (-4.78%)
ZM : 67.75 (-7.51%)
WDAY : 217.14 (-4.90%)
TGT : 95.72 (+1.53%)
MNST : 57.08 (-4.31%)
HPQ : 22.61 (-4.92%)
RIVN : 11.21 (-2.78%)
NCLH : 15.69 (-3.80%)
BAYN.D.DX : 20.090 (-5.56%)
Aptinyx Reports Results from Phase 2 Study of NYX-458 in Cognitive Impairment Associated with Parkinson's Disease and Dementia with Lewy Bodies and Provides Pipeline and Corporate Update Business Wire - Mon Feb 27, 2023

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced results from a Phase...

APTX : 0.0960 (+3.11%)
Aptinyx to Present at the SVB Securities Global Biopharma Conference Business Wire - Tue Jan 31, 2023

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Andy Kidd, M.D.,...

APTX : 0.0960 (+3.11%)
Preclinical Data from Aptinyx’s NMDA Receptor Modulators to be Presented at the 52nd Annual Meeting of the Society for Neuroscience Business Wire - Thu Nov 10, 2022

Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced upcoming poster presentations...

APTX : 0.0960 (+3.11%)
Aptinyx Reports Third Quarter 2022 Financial Results and Recent Highlights Business Wire - Tue Nov 8, 2022

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results for...

APTX : 0.0960 (+3.11%)
Clinical Evaluation of Aptinyx's NYX-783 for Treatment of Opioid Use Disorder to Be Funded by $5.6 Million NIH Grant Business Wire - Thu Nov 3, 2022

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced the finalization of a $5.6 million...

APTX : 0.0960 (+3.11%)
Aptinyx to Report Third Quarter 2022 Financial Results on Tuesday, November 8, 2022 Business Wire - Tue Oct 18, 2022

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will...

APTX : 0.0960 (+3.11%)
Aptinyx Completes Enrollment in Phase 2 Study of NYX-458 in Cognitive Impairment Associated with Parkinson’s Disease and Dementia with Lewy Bodies Business Wire - Thu Aug 25, 2022

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the completion of enrollment...

APTX : 0.0960 (+3.11%)
Aptinyx Reports Results from Phase 2b Study of NYX-2925 in Fibromyalgia Business Wire - Fri Aug 12, 2022

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced results from a Phase...

APTX : 0.0960 (+3.11%)

Barchart Exclusives

Should You Buy the Dip in Apple Stock in April 2025? Barchart - Sat Apr 5, 6:00AM CDT
Here is what you should do as Apple falls 22% from its 52-week high. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trader's Cheat Sheet: Your Secret Weapon for Smarter Trades
Wed, Apr 09, 2025 5:00 PM UTC
Reserve Your Spot